Effect of Tetanus Toxoid Vaccine on Neonatal Tetanus

Effect of Tetanus Toxoid Vaccine on Neonatal Tetanus Evaluation of the effect of Tetanus Toxoid vaccine on neonatal tetanus Clinical scenario Tetanus is a vaccine preventable disease caused by a ubiquitous spore-forming bacteria called Clostridium tetani (reference need). Due to its ubiquity, the disease cannot be eradicated (Roper et al. 2007). Tetanus that occurs in neonates between 3-28 days of life is termed neonatal tetanus (CDC, 1997) and the most common nidus of infection in neonates is through the freshly cut umbilical cord (Bennett et al. 1996; Roper et al. 2007). Substantial progress has been made towards the elimination of maternal and neonatal tetanus (MNT) by the WHO initiative, although it still remains a major problem in more than 30 developing countries (figure 1) (WHO, 2015). Figure 1. The global map sowing the advancement towards the elimination of maternal and neonatal tetanus. Source: WHO. (2015). [Online]. http://www.who.int/immunization/diseases/MNTE_initiative/en/index4.html Developed countries such as the United States of America, England and Denmark, have long ago eliminated tetanus linked neonatal deaths compared to developing countries (Pascual et al. 2003; Simonsen et al. 1987; Rushdy et al. 2003). Haws et al. (2007) mentioned that in areas where the prevalence of neonatal tetanus is common, vaccinating women against tetanus during pregnancy is likely to prevent the disease. Neonatal tetanus still remains one of the leading causes of infant mortality in many developing countries despite the fact that tetanus vaccine has been available for years (Stanfield et al. 1984). Hence, the aim of this critical appraisal is to evaluate the effect of tetanus toxoid vaccine given to pregnant women to provide effective protection and reduce deaths from neonatal tetanus in comparison to no vaccine. Focused Clinical Question Table 1: Search Strategy Inclusion and Exclusion Criteria Table 2: search and screening results Total number of studies = 3 (Blencowe et al., 2010; Maral et al., 2001 and Demicheli et al., 2013). Table 3: CASP screening tool for the appraisal of two Systematic Reviews and one Cross-sectional Study *A cross-sectional appraisal tool does not exist, therefore Maral et al., 2001 was appraised using the systematic review appraisal tool. Exclusions Summary of best evidence Blencowe et al., 2010 Systematic review Aim/Objective of the Systematic review: To evaluate the effect of Tetanus Toxoid vaccination of pregnant women or women of child bearing age on neonatal tetanus mortality. Study Design Search Strategy A range of appropriate databases were used such as PubMed, EMASE, Cochrane Libraries and World Health Organisation Regional Databases. Suitable search terms were used such as ‘Neonatal Tetanus, Tetanus Toxoid, Neonatal Mortality and Women’. Publications in any language were also included. Selection Criteria for inclusion of studies The PICO format (Patient, Intervention, Comparison and Outcome) was used in this review to identify the studies to be included as follows: Population – Neonates Intervention – At least two Tetanus Toxoid vaccine doses Comparison – Neonates born without Tetanus Toxoid vaccination Outcome – Mortality from Neonatal Tetanus Randomised trails and observational studies meeting the above criteria’s were considered in this review. Methods A systematic review of various databases was carried out to identify suitable studies meeting inclusion criteria Standardised abstraction forms were used for each outcome of interest for studies meeting the inclusion criteria Studies not meeting the inclusion criteria, studies which only reported serological outcomes and duplicate reports of studies or trails were all excluded Quality of individual studies and evidence were evaluated according to the CHERG version of the GRADE method to generate an approximate calculation of the effects in reducing neonatal mortality A meta-analysis was carried out using STATA version 10.0 statistic software and stated the mantel-haenszel pooled relative risk and corresponding 95% confidence intervals (CI) Findings Two studies which had no heterogeneity between them (p=0.16) i.e. a high-quality randomised controlled trial and a well-designed cohort study with adjustment for publication bias in its analysis, were joined into one meta-analysis to give an estimate of relative risk (RR)= 0.06 (95% CI 0.02-0.2) (Fig. 1). While, three case-control studies each with adjustment for publication bias showed a protective effect of two tetanus toxoid injections during pregnancy (odd ratio (OR) = 0.05 (0.005-0.4); OR=0.1 (0.03_0.4); OR=0.2 (0.03-0.7). Overall result A 94% reduction in neonatal tetanus mortality (95% CI 80-98%). The confidence interval of 95% for these results appear to be accurate.